Stock Events

Moleculin Biotech 

$4.58
41
-$0.07-1.51% Today

Statistics

Day High
4.66
Day Low
4.4
52W High
15.75
52W Low
4.28
Volume
10,562
Avg. Volume
42,599
Mkt Cap
10.36M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-5.09
-3.46
-1.82
-0.19
Expected EPS
-0.215
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBRX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap83.12B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Moleculin, including cancer, making it a direct competitor.
AMGEN
AMGN
Mkt Cap144.25B
Amgen focuses on human therapeutics, including treatments for cancer, which competes with Moleculin's cancer drug development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap99.17B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Moleculin's oncology focus.
Merck &
MRK
Mkt Cap318.6B
Merck operates in the pharmaceutical industry with a strong emphasis on cancer drugs, competing with Moleculin's product pipeline.
Pfizer
PFE
Mkt Cap147.23B
Pfizer is a global biopharmaceutical company with a broad range of drugs, including cancer treatments that compete with Moleculin's developments.
Novartis
NVS
Mkt Cap206.64B
Novartis is a healthcare company that offers treatments for a variety of conditions, including cancer, making it a competitor to Moleculin.
Abbvie
ABBV
Mkt Cap294.65B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, directly competing with Moleculin's focus areas.
Lilly(Eli) &
LLY
Mkt Cap690.11B
Eli Lilly is a global healthcare leader that develops drugs for cancer among other diseases, positioning it as a competitor to Moleculin.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a significant focus on oncology, competing with Moleculin.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals is known for its innovative medicines and therapeutic advancements, including in oncology, making it a competitor to Moleculin.

Analyst Ratings

21$Average Price Target
The highest estimate is $40.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Show more...
CEO
Employees
18
Country
US
ISIN
US60855D2009
WKN
000A2QQM0

Listings